You are here

Article info

Article menu

Download PDFPDF

Clinical science
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases

Authors

  • Rashmi Deshmukh Ophthalmology, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Darren Shu Jeng Ting Ophthalmology, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Ahmad Elsahn Ophthalmology, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Imran Mohammed Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Dalia G Said Ophthalmology, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Harminder Singh Dua Ophthalmology, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Harminder Singh Dua, Ophthalmology, University of Nottingham, Nottingham, Nottinghamshire, UK; harminder.dua{at}nottingham.ac.uk
View Full Text

Citation

Deshmukh R, Ting DSJ, Elsahn A, et al
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases
British Journal of Ophthalmology 2022;106:1087-1092.

Publication history

  • Received September 3, 2020
  • Revised February 11, 2021
  • Accepted February 17, 2021
  • First published March 9, 2021.
Online issue publication 
July 21, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.